^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

GENOMIC LANDSCAPE OF ENTRECTINIB RESISTANCE FROM CTDNA ANALYSIS IN STARTRK-2

Published date:
09/28/2019
Excerpt:
BRAF V600E and KRAS G12D mutations were detected at progression from a pancreatic cancer patient who had a partial response.
Trial ID: